Evidence map›Paper›PMID 39682753›Full record

ArticleCells2024

Stage-Dependent Fibrotic Gene Profiling of WISP1-Mediated Fibrogenesis in Human Fibroblasts.

Kirti Singh, Marta Witek, Jaladhi Brahmbhatt, Jacquelyn McEntire, Kannan Thirunavukkarasu, Sunday S Oladipupo

Abstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kirti SinghBiotherapeutics Enabling Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.ORCID 0009-0008-9183-5113
Marta WitekProtein Optimization, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.ORCID 0009-0000-2707-1536
Jaladhi BrahmbhattProtein Optimization, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.
Jacquelyn McEntireBiotherapeutics Enabling Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.
Kannan ThirunavukkarasuImmunology Research, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.ORCID 0009-0000-1503-1529
Sunday S OladipupoBiotherapeutics Enabling Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46225, USA.

Funding

Eli Lilly and Company (USA) N/A
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is the most common interstitial lung disease with unknown etiology, characterized by chronic inflammation and tissue scarring. Although, Pirfenidone and Nintedanib slow the disease progression, no currently available drugs or therapeutic interventions address the underlying cause, highlighting the unmet medical need. A matricellular protein, Wnt-1-induced secreted protein 1 (WISP1), also referred to as CCN4 (cellular communication network factor 4), is a secreted multi-modular protein implicated in multi-organ fibrosis. Although the precise mechanism of WISP1-mediated fibrosis remains unclear, emerging evidence indicates that WISP1 is profibrotic in nature. While WISP1-targeting therapy is applied in the clinic for fibrosis, detailed interrogation of WISP1-mediated fibrogenic molecular and biological pathways is lacking. Here, for the first time, using NanoString

Indexed as

CCN Intercellular Signaling ProteinsFibroblastsIdiopathic Pulmonary FibrosisProto-Oncogene ProteinsFibrosisGene Expression ProfilingHumansInterleukin-6LungSignal TransductionCCN4 protein, humanCCN Intercellular Signaling ProteinsInterleukin-6Proto-Oncogene Proteinsextracellular matrixfibroblastidiopathic pulmonary fibrosisinflammationmatricellular proteinWISP1/CCN4

Identifiers

PMID39682753
PMCPMC11640464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.